About: Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript.

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 27 August 2009

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) artículu científicu espublizáu en 2009 (ast) наукова стаття, опублікована в серпні 2009 (uk) scientific article published on 27 August 2009 (en) مقالة علمية نشرت في 27 أغسطس 2009 (ar)
publication date	wds:Q37369917-4950B0B6-4472-459F-A6FB-E78ACF8EC15D
publication date	2009-08-27 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37369917-F696155F-E5C0-4D85-A439-0FBDD7C40A1E
language of work or name	English
cites work	wds:Q37369917-0FD9E76D-BE44-4460-AD16-A1B2E05FE50E wds:Q37369917-10F26E11-A6C1-4CC1-BECA-F622FBB3C4C5 wds:Q37369917-12D50B3B-3D38-4C66-835B-3274D896FF6A wds:Q37369917-18B1B01F-2972-4745-9BEF-DDF0CC432E46 wds:Q37369917-21B9DB25-02DD-4C54-BC43-66A824F7F42E wds:Q37369917-25D580D3-0CE2-45CF-A301-C45A141D4160 wds:Q37369917-32D8A528-672E-4223-B95A-E0616A80493F wds:Q37369917-41A7B559-A1FF-4CF6-8EB9-2037CADFA8F2 wds:Q37369917-470AA582-04AE-406D-B843-A0138ED2E0C5 wds:Q37369917-4918FF1B-19EC-41C3-99A2-C9239299D1EC wds:Q37369917-6D14400C-2527-4313-BA52-5A40D972EE8D wds:Q37369917-7CA6D592-CA47-4BB2-BF4E-57A90ED66828 wds:Q37369917-8637995C-220E-4EAF-9EAD-790E6C68E267 wds:Q37369917-B3D88714-2D81-4D9F-95FC-3DCDA89BBBBD wds:Q37369917-CF251D48-6554-4D46-AE4F-A49D72A2DB5F wds:Q37369917-CF597130-AE07-4FE2-B24D-DD435ED30BA4 wds:Q37369917-D09B4046-F1DA-44A6-8EAB-F6B308215561 wds:Q37369917-EB4C332C-0B4D-41A4-BAD1-CAC32F50143C wds:Q37369917-EF173668-7769-45DE-87EA-B5ECED36AE39 wds:Q37369917-F53386FE-CE2D-44C4-A496-9052F607D55F wds:Q37369917-FA3B486B-A538-4D17-8708-2DA3ADEA2D8D wds:Q37369917-FCACF18B-025E-4AC7-A768-812393482FC5 wds:Q37369917-FF1A93AE-F0B7-4C09-8DC1-904CB82BC41C
cites work	Active transport of imatinib into and out of cells: implications for drug resistance Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia The molecular biology of chronic myeloid leukemia. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia Prognostic discrimination in "good-risk" chronic granulocytic leukemia. A polymorphism in exon b2 of the major breakpoint cluster region (M-bcr) identified in chronic myeloid leukaemia patients In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. The possible influences of B2A2 and B3A2 BCR/ABL protein structure on thrombopoiesis in chronic myeloid leukaemia. Differential molecular response of the transcripts B2A2 and B3A2 to imatinib mesylate in chronic myeloid leukemia. Correlation of BCR/ABL transcript variants with patients' characteristics in childhood chronic myeloid leukaemia. Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials The position of the M-BCR breakpoint does not predict the duration of chronic phase or survival in chronic myeloid leukemia Analysis of Bcr-abl type transcript and its relationship with platelet count in Mexican patients with chronic myeloid leukemia Analysis and comparison of clinicohematological parameters and molecular and cytogenetic response of two Bcr/Abl fusion transcripts. Relationship of the BCR gene breakpoint and the type of BCR/ABL transcript to clinical course, prognostic indexes and survival in patients with chronic myeloid leukemia Does the breakpoint within the major breakpoint cluster region (M-bcr) influence the duration of the chronic phase in chronic myeloid leukemia? An analytical comparison of current literature The location of the Philadelphia chromosomal breakpoint site and prognosis in chronic granulocytic leukemia Relationship of bcr breakpoint to chronic phase duration, survival, and blast crisis lineage in chronic myelogenous leukemia patients presenting in early chronic phase.
author name string	wds:Q37369917-4A3A491F-1091-4E95-A2C7-85DF29BBBAA2 wds:Q37369917-6A019273-908B-462C-995A-0D8F53B5BECA wds:Q37369917-74047E1E-E7CB-4FED-8B8C-07BEF67B9CAC wds:Q37369917-868FF992-5A54-4E36-BCA7-C9392CE7AF46 wds:Q37369917-C6752D5D-01C9-4439-BCE2-EAC979B86C30 wds:Q37369917-FC0D93C7-DB69-45AD-9463-78796E88E460
author name string	Lihui Wang Robert J Harris Richard E Clark Katy Knight Sarah J Watmough Andrea Davies
rdfs:label	Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. (en) Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. (nl) Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. (ast)
skos:prefLabel	Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. (en) Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. (nl) Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. (ast)
name	Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. (en) Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. (nl) Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. (ast)
author	wds:Q37369917-497BB439-7707-4E05-833A-7CC5EDB8EF59 wds:Q37369917-DE432217-960B-4599-B1D6-603646B338C8
author	Athina Giannoudis Claire M Lucas
title	wds:Q37369917-031EAF33-4872-45B5-9BC5-305B9DC5DF32
title	Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript (en)
page(s)	wds:Q37369917-C606EA40-AF66-498E-99B7-6EAB0310D87E
page(s)	1362-1367
instance of	wds:Q37369917-92797756-AA99-4C9B-BC1F-8D23CCF84DD0
instance of	scholarly article
main subject	wds:Q37369917-10758F69-8F43-4E2F-9F1E-E5E31D7BAEE9 wds:Q37369917-14B9A004-B065-40AB-A6AA-D68A1CDAECE2

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 171 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software